Q&A: BioCi­na’s new CEO Mark Wom­ack on the CD­MO he says is 'worth trav­el­ing over'

A hand­ful of CD­MOs have made changes at the top over the past few weeks, in­clud­ing Genezen and Cu­ria.

That al­so in­cludes Aus­tralian CD­MO BioCi­na, which an­nounced last week that Mark Wom­ack would be tak­ing the helm. Wom­ack pre­vi­ous­ly served as chief busi­ness of­fi­cer at AGC Bi­o­log­ics, CEO of In­di­an man­u­fac­tur­er Stelis Bio­phar­ma and most re­cent­ly, CEO at CD­MO KBI Bio­phar­ma and Se­lex­is SA.

BioCi­na com­plet­ed the takeover of a Pfiz­er man­u­fac­tur­ing fa­cil­i­ty in Ade­laide in 2021 and is now prep­ping for wider growth. End­points News sat down with Wom­ack to dis­cuss his new role, plans for the fu­ture, and how to com­pete in the wider CD­MO mar­ket. This in­ter­view has been edit­ed for brevi­ty and clar­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER